Scarica l'app Stockscreener
2.02
30.82%
-0.90
Dopo l'orario di chiusura:
1.99
-0.03
-1.49%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt - Investing.com Canada
Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation By Investing.com - Investing.com Canada
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs - Barron's
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com Canada
Why Is Foghorn Therapeutics Stock Tumbling Today?Foghorn Therapeutics (NASDAQ:FHTX) - Benzinga
Foghorn and Lilly Halt FHD-909 After Phase 1 Data - Minichart
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review - Yahoo Finance
FHTX Stock Slides As Traders Focus On Cash Runway And Charts - StocksToTrade
FHTX Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Why is Foghorn Therapeutics stock plummeting today? By Investing.com - Investing.com Canada
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs - TipRanks
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug - Yahoo Finance
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities - TradingView
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities - GlobeNewswire
Enterprise value to EBITDA forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Citizens reiterates Foghorn Therapeutics stock rating on trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Foghorn Therapeutics stock rating on trial data - Investing.com
Foghorn Therapeutics (FHTX) Slips 2.17% to $5.87 as Shares Approach Key Support ZoneStock Buy Zone - dars.gov.et
B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX) - The Globe and Mail
Price to book forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Precision Trading with Foghorn Therapeutics Inc. (FHTX) Risk Zones - Stock Traders Daily
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet - Yahoo Finance
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - vinanet.vn
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update - Traders Union
Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView
Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock Titan
Foghorn’s lung cancer trial advances; IND targeted for 2027 - stocktitan.net
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - Investing News Network
Foghorn Therapeutics (FHTX) Jumps 5.4% as Biotech Stock Approaches Key Resistance at $5.10IV Expansion Alert - careplusvn.com
Foghorn Therapeutics (FHTX) Rises 1.77% as Shares Hold Above Key Support at $4.38Dividend Arbitrage - dars.gov.et
Foghorn Therapeutics (FHTX) Slides 4.4% to $4.53, Approaching Key Support LevelOrder Block - vinanet.vn
Foghorn Therapeutics Inc. Revenue Breakdown – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Foghorn Therapeutics (FHTX) Declines 6.4% as Gene Regulation Biotech Tests Key Support at $4.21Force Index - vinanet.vn
FHTX Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesCore Business Growth - dars.gov.et
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics (FHTX) Expected to Release Earnings on Tuesday - MarketBeat
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):